Zynex (NASDAQ:ZYXI - Get Free Report) had its price objective lifted by equities researchers at HC Wainwright from $16.00 to $17.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price objective would suggest a potential upside of 97.90% from the company's current price.
Separately, Royal Bank of Canada cut their price target on shares of Zynex from $12.00 to $11.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th.
Read Our Latest Research Report on ZYXI
ZYXI opened at $8.59 on Friday. The business has a fifty day simple moving average of $7.96 and a 200-day simple moving average of $9.23. The firm has a market cap of $272.65 million, a PE ratio of 47.72 and a beta of 0.54. The company has a quick ratio of 3.22, a current ratio of 4.06 and a debt-to-equity ratio of 1.79. Zynex has a fifty-two week low of $7.04 and a fifty-two week high of $13.77.
Zynex (NASDAQ:ZYXI - Get Free Report) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. The business had revenue of $49.97 million during the quarter, compared to analyst estimates of $50.83 million. Zynex had a return on equity of 14.15% and a net margin of 3.12%. Zynex's revenue for the quarter was up .1% on a year-over-year basis. During the same quarter last year, the company posted $0.10 EPS. As a group, equities analysts predict that Zynex will post 0.2 EPS for the current fiscal year.
In other Zynex news, Director Joshua R. Disbrow acquired 7,000 shares of Zynex stock in a transaction that occurred on Monday, July 29th. The stock was purchased at an average cost of $8.32 per share, with a total value of $58,240.00. Following the purchase, the director now owns 72,000 shares in the company, valued at approximately $599,040. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Joshua R. Disbrow acquired 7,000 shares of the stock in a transaction that occurred on Monday, July 29th. The shares were purchased at an average cost of $8.32 per share, with a total value of $58,240.00. Following the completion of the transaction, the director now owns 72,000 shares of the company's stock, valued at approximately $599,040. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Anna Lucsok sold 8,083 shares of the company's stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total transaction of $64,906.49. Following the completion of the transaction, the chief operating officer now owns 16,980 shares in the company, valued at approximately $136,349.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 52.13% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of ZYXI. State Board of Administration of Florida Retirement System acquired a new position in Zynex in the 1st quarter worth about $137,000. Investment Partners Asset Management Inc. bought a new stake in shares of Zynex in the 3rd quarter valued at approximately $96,000. Hsbc Holdings PLC acquired a new position in Zynex in the second quarter worth approximately $113,000. Quest Partners LLC raised its position in Zynex by 646.7% during the second quarter. Quest Partners LLC now owns 12,926 shares of the company's stock valued at $120,000 after acquiring an additional 11,195 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Zynex by 56.4% in the first quarter. Principal Financial Group Inc. now owns 17,679 shares of the company's stock valued at $219,000 after acquiring an additional 6,378 shares during the last quarter. 29.68% of the stock is currently owned by hedge funds and other institutional investors.
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Zynex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zynex wasn't on the list.
While Zynex currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.